Selective neuronal vulnerability in Parkinson disease

被引:0
|
作者
D. James Surmeier
José A. Obeso
Glenda M. Halliday
机构
[1] Feinberg School of Medicine,Department of Physiology
[2] Northwestern University,undefined
[3] Centro Integral de Neurociencias A.C. (CINAC),undefined
[4] HM Puerta del Sur,undefined
[5] Hospitales de Madrid,undefined
[6] Mostoles and CEU San Pablo University,undefined
[7] Network Center for Biomedical Research on Neurodegenerative Diseases (CIBERNED),undefined
[8] Instituto Carlos III,undefined
[9] Brain and Mind Centre,undefined
[10] Sydney Medical School,undefined
[11] The University of Sydney,undefined
[12] School of Medical Sciences,undefined
[13] University of New South Wales and Neuroscience Research Australia,undefined
来源
Nature Reviews Neuroscience | 2017年 / 18卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Clinical Parkinson disease (cPD) is associated with both distributed Lewy pathology (LP) and neuronal death. There are no proven strategies of modifying either feature of the disease.Although there is consistency in the brain regions manifesting LP, there is considerable variability in its sequencing and severity. Moreover, the relationship between LP and the pathophysiology underlying symptoms is uncertain.The distribution of LP in cPD is not consistent with a simple prion model in which the spread of LP is retrograde and determined solely by the brain connectome.Neuronal death in cPD is less well characterized, but it is seen first in the substantia nigra, appearing later in a subset of neurons in the diencephalon, telencephalon and brainstem. Importantly, the pattern of neuronal death differs considerably in staging and to a lesser extent in distribution from that of LP.Many of the neurons that die in cPD exhibit a common set of traits, which include a long, highly branched axon, autonomous spiking, elevated calcium entry and basal mitochondrial oxidant stress. This set of traits may make these neurons vulnerable to cell death in association with LP, ageing, genetic mutations associated with cPD and/or environmental toxins.Therapeutic strategies aimed at altering the features of neurons that make them vulnerable to death and LP have the potential to slow or stop the progression of cPD.
引用
收藏
页码:101 / 113
页数:12
相关论文
共 50 条
  • [41] Selective neuronal vulnerability to oxidative stress in the brain
    Wang, Xinkun
    Michaelis, Elias K.
    FRONTIERS IN AGING NEUROSCIENCE, 2010, 2
  • [42] SELECTIVE NEURONAL VULNERABILITY IN THE LYSOSOMAL STORAGE DISEASES
    YOUNG, RSK
    WILLIAMS, RT
    NORMAN, MG
    ZALNERAITIS, EL
    KOLODNY, EH
    ANNALS OF NEUROLOGY, 1980, 8 (02) : 218 - 218
  • [43] Deciphering Differential Neuronal Vulnerability to AlphaSynuclein Pathology in Parkinson's Disease and Multiple System Atrophy
    Valerio, Fernanda
    Nelvagal, Hemanth
    Curless, Toby
    Chiraki, Nancy
    Real, Raquel
    Blunskyte, Modesta
    Gavriouchkina, Daria
    Hardy, John
    Jaunmuktane, Zane
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2025, 51
  • [44] Urate and Its Transgenic Depletion Modulate Neuronal Vulnerability in a Cellular Model of Parkinson's Disease
    Cipriani, Sara
    Desjardins, Cody A.
    Burdett, Thomas C.
    Xu, Yuehang
    Xu, Kui
    Schwarzschild, Michael A.
    PLOS ONE, 2012, 7 (05):
  • [45] Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease
    E Hermel
    J Gafni
    S S Propp
    B R Leavitt
    C L Wellington
    J E Young
    A S Hackam
    A V Logvinova
    A L Peel
    S F Chen
    V Hook
    R Singaraja
    S Krajewski
    P C Goldsmith
    H M Ellerby
    M R Hayden
    D E Bredesen
    L M Ellerby
    Cell Death & Differentiation, 2004, 11 : 424 - 438
  • [46] Functional Genomics of Brain Aging and Alzheimer's Disease: Focus on Selective Neuronal Vulnerability
    Wang, Xinkun
    Michaelis, Mary L.
    Michaelis, Elias K.
    CURRENT GENOMICS, 2010, 11 (08) : 618 - 633
  • [47] Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease
    Hermel, E
    Gafni, J
    Propp, SS
    Leavitt, BR
    Wellington, CL
    Young, JE
    Hackam, AS
    Logvinova, AV
    Peel, AL
    Chen, SF
    Hook, V
    Singaraja, R
    Krajewski, S
    Goldsmith, PC
    Ellerby, HM
    Hayden, MR
    Bredesen, DE
    Ellerby, LM
    CELL DEATH AND DIFFERENTIATION, 2004, 11 (04): : 424 - 438
  • [48] Complicity of α-synuclein oligomer and calcium dyshomeostasis in selective neuronal vulnerability in Lewy body disease
    Kenji Yamamoto
    Archives of Pharmacal Research, 2021, 44 : 564 - 573
  • [49] Complicity of α-synuclein oligomer and calcium dyshomeostasis in selective neuronal vulnerability in Lewy body disease
    Yamamoto, Kenji
    ARCHIVES OF PHARMACAL RESEARCH, 2021, 44 (06) : 564 - 573
  • [50] NEURONAL PLASTICITY AND PARKINSON DISEASE
    ANGLADE, P
    TSUJI, S
    AGID, Y
    HIRSCH, EC
    MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1995, 24 (2-3) : 251 - 255